Recordati Industria Chimica e Farmaceutica S.p.A.

BIT:REC Stock Report

Market Cap: €11.1b

Recordati Industria Chimica e Farmaceutica Future Growth

Future criteria checks 4/6

Recordati Industria Chimica e Farmaceutica is forecast to grow earnings and revenue by 14.1% and 7.1% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 41.5% in 3 years.

Key information

14.1%

Earnings growth rate

13.69%

EPS growth rate

Pharmaceuticals earnings growth12.7%
Revenue growth rate7.1%
Future return on equity41.46%
Analyst coverage

Good

Last updated26 Sep 2025

Recent future growth updates

Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 5.4% And Analysts Are Revising Their Forecasts

Aug 04
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 5.4% And Analysts Are Revising Their Forecasts

Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 13
Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Price Is Out Of Tune With Earnings

Sep 09
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Price Is Out Of Tune With Earnings

We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Aug 08
We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 5.4% And Analysts Are Revising Their Forecasts

Aug 04
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 5.4% And Analysts Are Revising Their Forecasts

Does Recordati Industria Chimica e Farmaceutica (BIT:REC) Have A Healthy Balance Sheet?

Jul 13
Does Recordati Industria Chimica e Farmaceutica (BIT:REC) Have A Healthy Balance Sheet?

Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.67

May 09
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.67

Here's Why Shareholders May Consider Paying Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) CEO A Little More

Apr 22
Here's Why Shareholders May Consider Paying Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) CEO A Little More

Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 16
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67

Mar 22
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67

Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?

Mar 19
Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?

Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Jan 05
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?

Dec 18
Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?
User avatar

Calculated Acquisitions And Market Expansions Set The Stage For Robust Financial Growth

Strategic acquisitions and market expansions enhance revenue growth, especially the rights to Enjaymo and early Isturisa approval in China.

We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Nov 18
We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60

Nov 14
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60

Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 13
Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar

Oct 31
Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar

Earnings and Revenue Growth Forecasts

BIT:REC - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273,0056407618239
12/31/20262,8225777067619
12/31/20252,6404766726929
6/30/20252,480407-297575N/A
3/31/20252,414418-265584N/A
12/31/20242,342417-279570N/A
9/30/20242,269423476530N/A
6/30/20242,224387114481N/A
3/31/20242,139389154528N/A
12/31/20232,082389102485N/A
9/30/20232,032375134510N/A
6/30/20232,005389438507N/A
3/31/20231,985340360456N/A
12/31/20221,853312367462N/A
9/30/20221,801331391485N/A
6/30/20221,702330422504N/A
3/31/20221,615393445491N/A
12/31/20211,580386404492N/A
9/30/20211,511377373475N/A
6/30/20211,460365303413N/A
3/31/20211,404334259425N/A
12/31/20201,449355272404N/A
9/30/20201,475389-112362N/A
6/30/20201,499391-84388N/A
3/31/20201,528388-101336N/A
12/31/20191,482369-125319N/A
9/30/20191,439328210318N/A
6/30/20191,399322202301N/A
3/31/20191,369318N/A346N/A
12/31/20181,352312N/A358N/A
9/30/20181,338307N/A362N/A
6/30/20181,333306N/A307N/A
3/31/20181,313297N/A277N/A
12/31/20171,288289N/A273N/A
9/30/20171,255275N/A244N/A
6/30/20171,217262N/A286N/A
3/31/20171,194250N/A273N/A
12/31/20161,154237N/A255N/A
9/30/20161,126229N/A266N/A
6/30/20161,096218N/A261N/A
3/31/20161,074212N/A258N/A
12/31/20151,048199N/A247N/A
9/30/20151,030190N/A231N/A
6/30/20151,019181N/A217N/A
3/31/20151,003170N/A198N/A
12/31/2014987161N/A179N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REC's forecast earnings growth (14.1% per year) is above the savings rate (2.9%).

Earnings vs Market: REC's earnings (14.1% per year) are forecast to grow faster than the Italian market (9.7% per year).

High Growth Earnings: REC's earnings are forecast to grow, but not significantly.

Revenue vs Market: REC's revenue (7.1% per year) is forecast to grow faster than the Italian market (5% per year).

High Growth Revenue: REC's revenue (7.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: REC's Return on Equity is forecast to be very high in 3 years time (41.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 03:31
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paola SagliettiBanca Akros S.p.A. (ESN)
Charles PitmanBarclays
Charles PitmanBarclays